替吉奥治疗晚期或复发性胃癌的疗效观察

Efficacy of S-1 for Advanced or Recurrent Gastric Cancer

目的分析晚期或复发性胃癌患者应用替吉奥单药治疗后的疗效、毒副反应。方法 28例患者根据体表面积给予替吉奥胶囊治疗,并评价患者的疾病控制率、无进展生存期和生存期。结果替吉奥对晚期胃癌和复发性胃癌的疾病控制率为39.3%。中位无进展生存期为4.0个月（95%CI,2.1~5.9个月）,晚期胃癌患者的中位无进展生存期为5.9个月（95%CI,3.1~8.5个月）,复发性胃癌的PFS中位值为3.1个月（95%CI,1.9~4.6个月）。中位生存期为10.5个月（95%CI,6.2~16.1个月）,晚期胃癌患者的中位生存期为10.0个月（95%CI,4.7~14.9个月）,复发性胃癌患者的中位生存期为14.2个月（95%CI,4.5~24.1个月）。Ⅲ、Ⅳ度毒副反应的发生率为10.7%。结论替吉奥治疗晚期或复发性胃癌安全有效,能延长患者生存期。

Objective To analyze the efficacy and toxicities of S-1 for advanced or recurrent gastric cancer. Methods Twenty-eight patients with advanced or recurrent gastric cancer were treated with S-1. The disease con- trol rate, progression-free survival and overall survival were analyzed. Results The disease control rate was 39.3%. The median progression-free survival was 4.0 months（95% CI, 2.1 to 59 months） ; the median progres- sion-free surviwd of the advanced patients was 5.9 months（95% CI, 3.1 to 8.5 months） ,and the median progres- sion-free surviwd of the recurrent patients was 3.1 months （95 % CI, 1.9 to 4.6 months）. The median overall sur- vival was 10.5 months（95% CI, 6.2 to 16.1 months） ; the median overall survival of the advanced patients was 10.0 months（95% CI, 4.7 to 14.9 months） ,and the median overall survival of the recurrent patients was 14.2 months（95% CI, 4.5 to 24.1 months）. The incidence rate of grade III or IV toxicities was 10.7%. Conclusion S-1 is safe and effective for the patients with advanced or recurrent gastric cancer.